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ABSTRACT 
 
Adenoid cystic carcinoma (ACC) of the breast rarely metastasizes and has been associated 
with excellent prognosis. We describe a patient with renal metastasis of primary breast ACC 
five years after the mastectomy. A detailed molecular genetic analysis of the primary and 
metastatic tumors demonstrated somatic mutations in two well known cancer genes associated 
with regulation of PI3K/AKT signaling pathway: 1) PIK3CA which encodes the catalytic 
alpha  subunit of the phosphoinositide-3-kinase and 2) PTEN, which encodes phosphatase and 
tensin homolog. The mutation identified in PIK3CA (Ex1+169 A>C) predicts an amino acid 
change from isoleucine to methionine at codon 31 (131M) and resides in the p85-binding 
domain of exon 1. The mutation identified in PTEN (IVS4-3 C>T) resides in intron 4 near the 
splice acceptor site of exon 5 and was associated with an aberrant PTEN transcript lacking 
exon 5, which is necessary for protein tyrosine phosphatase function and tumor suppressor 
properties of PTEN. Increased promoter methylation of PTEN was present in renal metastasis, 
coinciding with the decrease in the level of normal PTEN transcript.  
These coexistent mutations/epigenetic inactivations in PI3K/AKT pathway may be 
responsible for the unusually aggressive course of adenoid cystic carcinoma.. 
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INTRODUCTION 
 Adenoid cystic carcinoma (ACC) of the breast is a rare histologic type of breast 
carcinoma, comprising less than 1% of all mammary carcinomas.1 ACC is a basal-like breast 
carcinoma characterized by a distinct morphology and immunohistochemical profile.2 ACC is 
usually associated with a very good prognosis.3 Distant metastases are very rare and usually 
affect the lungs1. Only several cases with high grade tumors and distant metastases have been 
published, and only one case with symptomatic metastasis to the kidney has previously been 
reported.4 We report here a case of ACC of the breast with symptomatic renal metastasis, and 
for the first time show coexistent mutations in genes encoding phosphoinositide-3-kinase 
catalytic alpha subunit (PIK3CA) and phosphatase and tensin homolog (PTEN). Both 
PIK3CA and PTEN are integral part of the mammalian target of rapamycin (mTOR) signaling 
pathway.5 MTOR, a protein kinase of the PIK3/Akt signaling pathway, plays a central role in 
controlling malignant growth, cell cycle progression and proliferation.5  
CASE HISTORY 
 76-year-old woman presented with abdominal pain, painless hematuria and urinary 
frequency. CT scan showed a 6 cm expansive, poorly circumscribed tumor of the right kidney 
that was considered a primary renal carcinoma. Radical nephrectomy was performed and 
subsequent pathologic examination revealed a 90x48x40 mm, gray-white, hemorrhagic tumor 
involving pelvicalyceal system and cortex and medulla of the upper part of the kidney. 
Review of patient’s medical records showed that she underwent a mastectomy at a different 
institution for 1. 8 cm primary mammary adenoid cystic carcinoma (pT1c N0 MX R0) 5 years 
prior to current surgery. The patient did not receive any adjuvant therapy. Original formalin 
fixed paraffin embedded (FFPE) tissue blocks were obtained and morphologic, 
immunohistochemical and molecular analyses were then performed to compare these 2 
tumors. 
METHODS 
Immunohistochemistry 
Immunohistochemistry was performed using the standard avidin-biotin complex (ABC) 
detection system and diaminobenzidine tetrahydrochloride (DAB) chromagen. Table 1 lists 
antibodies used and results of staining in both primary and metastatic tumors. The expression 
levels of cyclooxygenase-2 (COX-2) and PTEN were measured on immunohistochemically 
stained tissue slides using the Automated Cellular Imaging System (ACIS, ChromaVision 
Medical Systems, Inc., San Juan Capistrano, CA). 
Molecular genetic analysis 
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Patient samples and DNA and RNA preparation.  DNA extractions from cancer and 
normal tissues were performed following manual microdissection to differentiate somatic 
from germ-line mutations. Tissue samples were digested with Proteinase K at 55°C overnight 
with continuous agitation (120 rpm). DNA was purified and concentrated using an Amicon 
Microcon YM-30 column (Millipore Corp., Billerica, MA).  RNA was extracted from FFPE 
tisuses using the Paraffin Block RNA Isolation  kit according to the manufacturer's 
instructions (Ambion, Austin, TX). Any trace gDNA was removed from each aliquot of 
extracted RNA with DNase I using a commercial DNA-free Kit (Ambion). 
PCR  amplification of selected cancer genes.  Primer pairs were designed to amplify 
selected exons of the following genes:  KIT (ex 8-17); PDGFRA (ex 12, 14, 18); EGFR exons 
18-21, ERBB2 (ex 18-23); KRAS (ex 2-3); NRAS (ex 2-3); BRAF (ex 11, 15); PIK3CA (ex 
1, 9, 20); PTEN (ex 2-8); P53 (ex 5-8); and APC (ex 15).  Amplicons included 50 bp of 
intronic sequence to allow for detection of mutations residing in/near splice junction regions. 
Primer selection was performed with MutationDiscovery.com, a web-based Software 
(Transgenomic, Inc., Omaha, NE) which incorporates Primer 3 oligonucleotide selection and 
design criteria. Specificity and yield of each PCR product was routinely assessed by gel 
electrophoresis (2% agarose, 1X TAE buffer). 
Mutation scanning by Surveyor nuclease analysis and fragment analysis.  
Heteroduplexed PCR products were combined with 15 U of Surveyor Nuclease  and 1µl 
Enhancer  (Transgenomic), then incubated at 42°C for 20 min. Digestions were terminated 
with 2 µl Stop solution (0.5 M EDTA at pH 8.0) and analyzed on a Transgenomic WAVE 
System equipped with a High Sensitivity Detection module (WAVE-HS) for fluorescent 
detection of ds-DNA fragments. This scanning methodology has shown a limit of detection of 
1 mutant copy in 100-200 total copies.  
Mutation identification by DNA sequencing. PCR products were purified and cycle 
sequenced with amplicon specific primers. Sequencing products were run on an ABI 3100 
Genetic Analyzer.  Data were analyzed using Sequencher (GeneCodes, Ann Arbor, MI) and 
by manual review of chromatograms. 
PTEN cDNA analysis by RT-PCR. The nucleotide sequences and exon-intron boundaries of 
PTEN and GAPDH were derived from NCBI (http://www3.ncbi.nlm.nih.gov/). Primers 
(SigmaGenosys, The Woodlands, TX) spanning exonic junctions were designed to amplify 
fragments representing selected regions of the PTEN coding sequence (Table 2). RT-PCR was 
performed using the One-Step kit (Invitrogen, Carlsbad, CA) and end products were analyzed 
on the WAVE-HS and by DNA sequencing. 
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PTEN promoter methylation analysis by DHPLC and DNA sequencing.   
The methylation status of the PTEN promoter was examined by analyzing the sequence 
context of PCR products obtained from sodium bisulfite modified genomic DNA. The 
sulfonated DNA was recovered using the Wizard DNA clean-up system (Promega, Madison, 
WI) and the conversion reaction was completed by desulfonating in 0.3 M NaOH for 10 
minutes at room temperature. The DNA was ethanol precipitated and resuspended in water. 
PCR was done using specific primers designed outside of any CpG islands to amplify both 
methylated and unmethylated promoter sequences. Final PCR products were analyzed by 
DHPLC on a WAVE System in which allelic differences in methylation are detected due to 
the sequence-dependent separation characteristics of the DNASep DHPLC column. To obtain 
information regarding differential methylation across the PTEN promoter region, PCR 
products were also bi-directionally sequenced.    
RESULTS 
Microscopically, the renal tumor was composed of small epithelial cells that formed 
microcysts with centrally located PAS positive substances. The tumor was organized in both 
cribriform and solid patterns, but no sarcomatoid areas were noted. Differential diagnostic 
considerations included primary renal carcinoma (renal medullary carcinoma and mucinous 
tubular and spindle cell carcinoma) and metastatic adenoid cystic carcinoma. Both mammary 
and renal tumors (Figure 1A) showed strong positivity for c-kit, p63, CK5/6, CK18, SMA, 
Vimentin, E-cadherin and B-catenin. ER, PR and ERBB2 were not detected. These results are 
consistent with basaloid type of mammary carcinoma and confirmed the morphologic 
diagnosis of metastatic ACC to the kidney. 
COX2 expression was stronger in the metastasis than in the primary tumor. In primary ACC 
35% of cells were positive with the relative intensity 60.5±1.9 (in the most intensely stained 
part of the tumor) while in the renal metastasis COX2 was detected in nearly all cells with 
relative intensity 73.3±2.2. PTEN expression in primary and metastatic cancer was detected in 
the similar proportion of cells (41% and 37%, respectively), but the relative intensity was 
lower in metastatic cancer (75.3 vs. 92). 
Molecular analyses revealed the following gene mutations in both primary adenoid cystic 
carcinoma of the breast and  renal metastasis: 1. PIK3CA: Ex1+169 A>G predicting an amino 
acid substitution of isoleucine with methionine at codon 31(I31M) and 2. PTEN (IVS4-3 C>T 
near the splice acceptor site of exon 5 (Figures 1B and 1C, respectively). No mutations were 
found in normal breast and kidney tissues. In addition,  neither primary nor metastatic tumors 
showed mutations  in KIT, PDGFRA, EGFR, ERBB2, KRAS, NRAS, BRAF, P53 and APC 
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genes.  Analysis of PTEN cDNA amplified by RT-PCR showed aberrant transcript that lacked 
exon 5 in both the primary and metastatic cancers (Figure 1D). This would suggest that the 
PTEN splice acceptor mutation present in both samples is affecting processing of PTEN 
mRNA, with exon 5 not being included. The deleted region encodes PTEN amino acids 85-
164 and is essential for protein tyrosine phosphatase function and overall tumor suppression. 
Normal PTEN transcript, presumably derived from the non-mutated allele was also detected 
in both specimens. The amount of normal PTEN in renal metastasis appeared to be reduced 
relative to levels detected in primary breast tumor. Additional molecular evidence supporting 
the reduction of PTEN transcript in the metastasis comes from detailed analysis of promoter 
methylation. A distinct difference in the degree of methylation across the 3 regions of the 
PTEN promoter that contains the CpG residues was observed between the primary and 
metastic ACC (data not shown). Of twenty seven CpG islands evaluated, 63 % were 
methylated (fully or partially) in the primary tumor while 93% were methylated in the renal 
metastasis. 
 
DISCUSSION  
 Although ACC shows a distinct morphological pattern, its diagnosis, particularly in 
the case of a remote, isolated renal metastasis, presents a significant diagnostic challenge. 
Only one case with symptomatic renal and lung metastases has previously been reported.4 
Furthermore, renal medullary carcinoma and mucinous tubular and spindle cell carcinoma 
may exhibit morphologic features similar to high grade adenoid cystic carcinoma. ACC is 
usually composed of two population of the cells (myoepithelial and epithelial) that form 
circumscribed clusters of cells arranged in solid, cribriform, tubular and trabecular 
arrangements although one pattern can predominate2. Immunohistochemical documentation of 
two cell populations in our case was extremely helpful in distinguishing metastatic ACC from 
rare primary renal carcinomas with ACC-like growth patterns.  
ACC of the breast fulfills the criteria for the diagnosis of basal-like breast carcinoma as 
recently proposed (ER, PR and HER2/neu negative and p63, CK5/6, SMA and KIT 
positive).6,7 Classification of breast carcinoma based on gene expression patterns identified 
five different subtypes of breast cancer including: luminal type (A and B), ERBB2 type, 
basal-like and normal-like type. Basal-like carcinomas are distinct clinical and pathologic 
entity that exhibits significantly worse outcome than luminal type carcinomas.6,8 It is then 
paradoxical that ACC of the breast which is immunophenotypically classified as basal cell 
type cancer, have been particularly associated with favorable outcome.3 Therefore, only 
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detailed molecular genetic analysis such as the one performed in our study could provide 
additional important prognostic and potentially useful therapeutic information in an individual 
case. 
To our knowledge, the mutations in PTEN (IVS4-3 C>T) and PIK3CA (I31M) have not been 
previously detected neither in salivary gland nor breast ACC, and other cancer types. Our case 
is the first case that demonstrated mutations of these two genes in both primary and metastatic 
ACC. Furthermore, our case of ACC demonstrated two coexistent mutations in mTOR 
signaling pathway which rarely occurs. Several studies have pointed out that PIK3CA 
mutations were mutually exclusive with the mutations of PTEN, suggesting that oncogenic 
signaling occur either through activation of PIK3CA or inactivation of PTEN.9 However, 
recently published studies in endometrial carcinoma demonstrated that coexistent mutations 
of PIK3CA and PTEN genes are indeed possible.10 Our case also showed that such 
combination can also occur in mammary ACC. Furthermore, we showed that reduced 
expression of PTEN can also occur through increases in promoter methylation. PTEN and 
PIK3CA are two important tumor suppressor genes and oncogenes in the mammalian target of 
rapamycin (mTOR) signaling pathway.5 MTOR is a protein kinase that has a central role in 
controlling cancer growth and progression. It integrates signals from growth factors, energy 
stores and hypoxia.5 
Phosphoinositide kinase (PIK) is a lipid kinase that phosphorylates the inositol ring of 
phosphoinositides, acting as signal transducers. Mutational activation of PIK3CA is essential 
for carcinogenesis in some cancers. PIK3CA mutations are common in solid tumors and 
several have been shown to activate AKT, leading to growth-factor independent growth, 
inhibition of apoptosis and increased cell invasion and metastasis. 11 PIK3CA mutations have 
been detected in 8-40% of breast carcinomas and are associated with poor outcome.12 Saal et 
al9 identified PIK3CA mutations in 26% of 342 breast carcinoma specimens at about equal 
frequency irrespective of the tumor stage.  
PIK3 proteins consist of the family of proteins divided intro three classes that differ in its 
structure, tissue distribution, mechanism of action and its function. The most important PIK3 
proteins are those related to proliferation and carcinogenesis including class IA – the catalytic 
subunit p110α and its associated regulatory subunit p85. Activation of class IA proteins might 
activate several signaling pathways including AKT and Rictor-mTOR complex.5,11  
PI3-AKT signals govern several transcription factors including forkhead box (FOXO) 
proteins and nuclear factor κB (NFκB).13 NFκB acts as a positive regulator of cell survival, 
proliferation, cellular invasion and angiogenesis. Several studies demonstrated that Akt 
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signals through NFκB in order to induce cyclooxygenase-2 (COX-2) expression in mutated 
PTEN tumor cells.14 COX-2 significantly contributes to tumorigenesis through increased 
angiogenesis, invasiveness and inhibition of apoptosis.14 Our case demonstrated higher COX-
2 expression in the metastasis than in the primary tumor (Figure 1A). 
Although PTEN gene is one of the most commonly mutated genes in human tumors,15 its 
importance in ACC has not been described. Approximately 50% of breast carcinomas carry a 
mutation or loss of at least one copy of the PTEN gene which results in PIK3 activation.16 
PTEN mutations are often associated with an aggressive metastatic tumor phenotype since 
PTEN might interfere with focal adhesion kinase (FAK) and Shc functions enabling increased 
cell motility and spreading.15 Inactivation of PTEN might also result in increased cell cycle 
progression through the Akt-dependent phosphorylation and inactivation of glycogen synthase 
kinase-3 (GSK-3) which, in turn, leads to cyclin D1 stabilization.15 It also has a pivotal role in 
apoptosis since the loss of PTEN results in an increased PIP3 concentration and in Akt 
activation, leading to protection from various apoptotic stimuli.15 In our case we demonstrated 
increased methylation of PTEN gene promoter associated with reduced expression of PTEN 
protein in the metastasis compared to the primary tumor. A complete loss of PTEN is more 
frequent in metastatic than in primary tumors16 and in cases of breast carcinomas where 
decreased PTEN expression was associated with increased neoangiogenesis and poor clinical 
outcome.  
Results of such in-depth molecular analysis may have additional therapeutic implications. No 
mutations were observed in genes encoding the receptor tyrosine kinases, KIT and PDGFRA, 
known targets of imatinib mesylate inhibition (Gleevec) suggesting a limited response to this 
targeted therapy based upon clinical data of other cancer types (e.g. gastrointestinal stromal 
tumors, small cell lung carcinoma, melanoma).  Despite consistent expression of c-kit in 
ACC3, recent clinical trials showed no clinical benefit from Gleevec therapy in advanced head 
and neck ACC.17 No mutations were observed in the gene encoding the receptor tyrosine 
kinase, EGFR, a known target of both gefitinib and erlotinib, suggesting a limited response to 
this targeted therapy based upon clinical data from other cancer types (e.g. non-small cell 
carcinoma of the lung). 
In vitro and clinical studies confirmed that deregulation of the PI3K/PTEN/Akt pathway was 
associated with resistance to doxorubicin and tamoxifen, drugs commonly used in metastatic 
breast cancer therapy.18 This may have significant implications since chemotherapy and 
hormonal therapy are basic modalities for the treatment of metastatic breast carcinoma. On 
the other side, specific mutations we detected in our case, give new insights in both breast 
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carcinogenesis and novel therapeutic modalities. Thus, rapamycin, which acts as mTOR 
inhibitor, might have promising antitumor activity in subset of tumors with upregulated 
PIK3/AKT/mTOR signaling pathway. Also, three rapamycin analogs, temsirolimus (CCI-779, 
Wyeth), everolimus (RAD001, Novartis Pharma AG) and AP23573 (Ariad Pharmaceuticals) 
have been included in clinical trials for the treatment of cancer.5 To date, clinical trials results 
showed that mTOR inhibitors were well tolerated and might induce prolonged stable disease 
and tumor regressions in cancer patients.5  
Other components of this vital signaling pathway might also become the potential targets for 
specific small molecules. Thus, the mutated p110alpha proteins are ideal targets for such 
inhibitors that discriminate between the oncogenic and the wild-type forms of the enzyme.  
In summary, we report a case of metastatic ACC of the breast characterized by coexistent 
mutations in two important genes of mTOR signaling pathway (PIK3CA and PTEN) which 
might be responsible for the aggressive clinical course. Breast ACC is a triple negative 
(ER/PR/HER2), basal-like carcinoma that responses poorly to the conventional and even 
some targeted chemotherapies. Novel molecular targets identified in this case, may provide 
potential for therapeutic intervention(s). 
REFERENCES 
1. Sumpio BE, Jennings TA, Sullivan PD, Merino MJ: Adenoid Cystic Carcinoma of the 
Breast. Ann Surg 1987, 205:295-301 
2. Azoulay S, Laé M, Fréneaux P, Merle S, Al Ghuzlan A, Chnecker C, Rosty C,  
Klijanienko J, Sigal-Zafrani B, Salmon R, Fourquet A, Sastre-Garau X, Vincent-
Salomon A. KIT is highly expressed in adenoid cystic carcinoma of the breast, a 
basal-like carcinoma associated with a favourable outcome. Mod Pathol 2005, 
18:1623-31 
3. Page DL: Adenoid cystic carcinoma of breast, a special histopathologic type with 
excellent prognosis. Breast Cancer Res Treat 2005, 93:189-90 
4. Herzberg AJ, Bossen EH, Walther PJ: Adenoid cystic carcinoma of the breast 
metastatic to the kidney. A clinically symptomatic lesion requiring surgical 
management. Cancer 1991, 68:1015-20 
5. Dancey JE: Therapeutic Targets: MTOR and Related Pathways. Cancer Biol Ther 
2006, 5:e1-e9 
6. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, 
van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, 
Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas 
  10 
distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 
2001, 98:10869-74 
7. Sørlie E: Molecular portraits of breast cancer: tumor subtypes as distinct disease 
entities. Eur J Cancer 2004, 40:2667-75 
8. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE: 
Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin 
Pathol 2006, 59:729-3548 
9. Saal LH, Holm K, Maurer M,  Memeo L, Su T, Wang X, Yu JS, Malmstrom PO,  
Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R: PIK3CA mutations 
correlate with hormone receptors, node metastasis and ERBB2, and are mutually 
exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65:2554-59 
10. Oda K, Stokoe D, Taketani Y, McCormick F: High frequency of coexistent mutations 
of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005, 65:10669-
73 
11. Bader AG, Kang S, Zhao L, Vogt PK: Oncogenic PI3K deregulates transcription and 
translation. Nature Rev Cancer 2005, 5:921-29 
12. Li SY, Rong M, Grieu F, Iacopetta B: PIK3CA mutations in breast cancer are 
associated with poor outcome. Breast Cancer Res Treat 2006, 96:91-95 
13. Kane LP, Shapiro VS, Stokoe D, Weiss A: Induction of NF-kappa B by the Akt/PKB 
kinase. Curr Biol 1999, 9:601-4 
14. Germain-St, ME, Gagnon V, Parent S, Asselin E: Regulation of COX-2 protein 
expresion by Akt in endometrial cancer cells is mediated through NFκB/IκB pathway. 
Mol Cancer 2004, 3:7 
15. Cristofano AD, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell 
2000, 100:387-90 
16. Pandolfi PP: Breast Cancer – Loss of PTEN predicts resistance to treatment. N Engl J 
Med 2004, 351:2337-8  
17. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, 
Pond GR,  Murgo A, Siu LL: Imatinib Mesylate in Patients With Adenoid Cystic 
Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase 
II Consortium Study. J Clin Oncol 2005, 23:585-90 
18. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic 
PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F,  
  11 
Libra M: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant 
transformation and drug resistance. Adv Enzyme Regul 2006, 46:249-79 
Acknowledgements 
 We thank Jill Hempel, Stephanie Edstrom and Asja Pašanović for their excellent 
technical assistance.   
 
 
Figure Legend 
Figure 1. A) COX-2 expression (IHC stain, 20x) in kidney metastasis of ACC from the breast. 
Inset - Photomicrograph of the primary ACC in the breast (H&E, 20x). B) PIK3CA mutation 
detection and sequencing data. C) PTEN mutation detection and sequencing data. D) RT-PCR 
of PTEN cDNA transcript showing exon 5 deletion and aberrant transcript that lacks exon 5 in 
both the primary and metastatic cancers. 
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Table 1. Antibodies and staining results in primary and metastatic ACC. 1DAKO, Glostrup, 
Denmark; 2Cell Marque, Hot Spring, AR; 3Cayman Chemical, Ann Arbor, MI; 
aACIS relative stain intensity: 92.7 (in primary tumor) vs. 75.3 (in metastasis); b ACIS 
intensity: 60.5 (in primary tumor) vs. 73.3 (metastasis) 
 
Immunohistochemical 
marker 
Clone Dilution Primary 
ACC 
Metastatic 
ACC 
Vimentin V9, monoclonal1   +++ +++ 
C-kit (CD117) A-4502, polyclonal1   +++ +++ 
E-cadherin NHC-38, monoclonal1  +++ +++ 
Β-catenin Β-catenin-11  +++ +++ 
CK5/6 D5/16B41   -/+ +++ 
Estrogen Receptor 1D5, monoclonal1  - - 
Progesterone Receptor pgR636, monoclonal1  - - 
HER2/neu Polyclonal 
LOT0002556671 
 - - 
p63 4A4, monoclonal1  +++ +++ 
Smooth Muscle Actin 1A4, monoclonal1  ++ ++ 
PTEN Polyclonal2  ++a + a 
Cox-2 polyclonal rabbit IgG3  +b ++ b 
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Table 2. Oligonucleotide primers used for amplification of PTEN cDNA. The selected primers were 
used to PCR amplify cDNA fragments representing selected regions (exons 3 through 7) of the PTEN 
coding sequence. 
 
 
 
 
 
 
 
 
Primer ID Primer sequence (5' > 3') Tm (◦C) Length (nt) 
forward primers   
   
cPTEN-ex3f GGATTCAAAGCATAAAAACCATTAC 62.3 25 
cPTEN-ex4f GCTGAAAGACATTATGACACCGC 66.5 23 
cPTEN-ex5f GATCTTGACCAATGGCTAAGTGA 64.1 23 
reverse primers 
    
cPTEN-ex5r TACAGTGAATTGCTGCAACATGA 65.2 23 
cPTEN-ex6r TTCCGCCACTGAACATTGGAA 69.6 21 
exon junction reverse primers 
    
cPTEN-ex4-5r GTCTTCAAAAGGATATTGTGCAACTCTG 67.3 28 
cPTEN-ex5-6r GGAATAGTTACTCCCTTTTTGTCTCTG 63.9 27 
cPTEN-ex6-7r CAAACTGAGGATCTGCAGTTCC 64.9 22 
